Actively Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Led by Corcept Therapeutics · Updated on 2026-04-14
270
Participants Needed
49
Research Sites
85 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
CONDITIONS
Official Title
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients with histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma (Arms A and B) or stage III/IV recurrent or metastatic endometrial cancer (Arm C)
- For Arm A: platinum-resistant disease
- For Arm B: platinum-sensitive disease with progression during poly(ADP-ribose) polymerase (PARP) inhibitor treatment
- Life expectancy of at least 3 months
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Able to swallow and retain oral medication
- 1 to 3 lines of prior systemic anticancer therapy for Arms A and B
- 1 to 2 lines of prior systemic anticancer therapy for endometrial cancer (Arm C)
- Prior treatment with a platinum agent and an approved anti-Programmed Cell Death Ligand 1 (PD[L]1) antibody (Arm C)
- Must consent to provide formalin-fixed paraffin-embedded (FFPE) tumor tissue or recently cut sections (Arm C)
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential
You will not qualify if you...
- Progression while receiving weekly paclitaxel or nab-paclitaxel (Arm A and B only for Arm A)
- Prior enrollment in a relacorilant clinical trial
- Anticancer therapy-related toxicities not resolved to grade 1 or less
- Surgery within 4 weeks before enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent corticosteroid treatment
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Peripheral neuropathy greater than Grade 1
- Hypertension of 150 mm Hg systolic or higher, or 100 mm Hg diastolic or higher (Arms A and B)
- Uncontrolled conditions that may affect safety or trial results
- Bowel obstruction within 12 weeks prior to study entry
- Ascites or pleural effusions requiring therapeutic paracentesis
- Untreated or symptomatic central nervous system metastases (except Arm C patients who have completed local therapy and stopped corticosteroids for at least 4 weeks)
- History of other malignancies within 3 years prior to enrollment
- Receipt of live vaccines within 30 days before study start date
- Patients with central nervous system metastases are not eligible unless criteria met (Arm C)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 49 locations
1
004
Birmingham, Alabama, United States, 35233
Actively Recruiting
2
150
Palo Alto, California, United States, 94304
Actively Recruiting
3
014
San Francisco, California, United States, 94143
Actively Recruiting
4
544
Fort Myers, Florida, United States, 33901
Actively Recruiting
5
335
Miami Beach, Florida, United States, 33140
Actively Recruiting
6
543
West Palm Beach, Florida, United States, 33041
Actively Recruiting
7
518
Minneapolis, Minnesota, United States, 55404
Actively Recruiting
8
334
Kansas City, Missouri, United States, 64132
Actively Recruiting
9
521
St Louis, Missouri, United States, 63110
Actively Recruiting
10
292
Albuquerque, New Mexico, United States, 97102
Actively Recruiting
11
304
Centerville, Ohio, United States, 45459
Actively Recruiting
12
517
Eugene, Oregon, United States, 97401
Actively Recruiting
13
127
Pittsburgh, Pennsylvania, United States, 15213
Actively Recruiting
14
522
Fairfax, Virginia, United States, 22031
Actively Recruiting
15
300
Norfolk, Virginia, United States, 23502
Actively Recruiting
16
121
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
17
328
Aalst, Belgium, 9300
Actively Recruiting
18
326
Charleroi, Belgium, 6000
Actively Recruiting
19
325
Hasselt, Belgium, 3500
Actively Recruiting
20
108
Leuven, Belgium, 3000
Actively Recruiting
21
306
Lille, France, 59000
Actively Recruiting
22
307
Nancy, France, 54100
Actively Recruiting
23
310
Nice, France, 06100
Actively Recruiting
24
324
Pierre-Bénite, France, 69495
Actively Recruiting
25
323
Plérin, France, 22190
Actively Recruiting
26
308
Toulouse, France, 31059
Actively Recruiting
27
519
Aachen, Germany, 52074
Actively Recruiting
28
255
Berlin, Germany, 10117
Actively Recruiting
29
520
Kempten, Germany, 87439
Actively Recruiting
30
321
Catania, Italy, 95126
Actively Recruiting
31
122
Milan, Italy, 20141
Actively Recruiting
32
516
Milan, Italy, 20159
Actively Recruiting
33
295
Pavia, Italy, 27100
Actively Recruiting
34
124
Rome, Italy, 00168
Actively Recruiting
35
293
Torino, Italy, 10128
Actively Recruiting
36
319
Treviso, Italy, 31100
Actively Recruiting
37
341
Gdynia, Poland, 81-519
Actively Recruiting
38
329
Siedlce, Poland, 08-MO
Actively Recruiting
39
396
Seoul, Gangnam-gu, South Korea, 06351
Actively Recruiting
40
397
Gyeonggi-do, Goyang-si, South Korea, 10408
Actively Recruiting
41
399
Seoul, Jongno-gu, South Korea, 03080
Actively Recruiting
42
523
Seoul, Seocho-gu, South Korea, 06591
Actively Recruiting
43
398
Seoul, Seodaemun-gu, South Korea, 03722
Actively Recruiting
44
403
Seoul, Songpa-gu, South Korea, 05505
Actively Recruiting
45
349
Badalona, Spain, 08916
Actively Recruiting
46
115
Barcelona, Spain, 08035
Actively Recruiting
47
114
Madrid, Spain, 28034
Actively Recruiting
48
558
Valencia, Spain, 46010
Actively Recruiting
49
330
Valencia, Spain, 46026
Actively Recruiting
Research Team
C
Corcept Therapeutics
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here